The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Oxis Turbohaler 12, inhalation powder

AstraZeneca ABPA1019/015/002

Main Information

Trade NameOxis Turbohaler 12, inhalation powder
Active SubstancesFormoterol fumatrate dihydrate
Dosage FormInhalation powder
Licence HolderAstraZeneca AB
Licence NumberPA1019/015/002

Group Information

ATC CodeR03AC Selective beta-2-adrenoreceptor agonists
R03AC13 formoterol


License statusAuthorised
Licence Issued10/03/2002
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back